2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Biological Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5583 Chronic myelomonocytic leukemia is characterized by phenotypic diversity of immature blast populations that dictate disease evolution trajectories and are depleted by combined BCL2 and purine metabolism inhibition

Guillermo Montalban-Bravo, MD, Sanam Loghavi, MD2, Feiyang Ma3, Beenu Thakral, MD4, Chenxuan Zang5, Ziyi N/A Li6, Kelly Sharon Chien, MD7, Gautam Borthakur, MD8, Ghayas C. Issa, MD9, Elias Jabbour, MD10, Courtney DiNardo, MD, MSCE11, Nicholas Short, MD12, Danielle Hammond, MD13, Alex Bataller, MD, PhD14, Alexandre Bazinet, MD15, Ian Bouligny, M.D.16, Sa Wang, MD17, Wei Wang, MD, PhD18, Carlos Bueso-Ramos, M.D., Ph.D.19, Pezhman Hosseinpoor20, Hsinyi Lu21, Hui Yang, MD, PhD22, Yue Wei, PhD23, Kirbie Linthicum24, Cara Haymaker25, Tapan Kadia I, MD26, Guillermo Garcia-Manero, MD27
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Northwestern University, Chicago, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic stem/progenitor-cell (HSPC) neoplasm with high risk of transformation to acute myeloid leukemia (AML). CMML transformation results from the expansion of HSPCs or monocyte-committed precursors, through preferential RAS-pathway (BRAF, CBL, KRAS, NF1, NRAS, PTPN11) mutant (RASpMT) clone selection, under hypomethylating agent (HMA) therapeutic pressure. As in AML, expansion of RASpMT monocyte-biased clones confers venetoclax (VEN)-resistance through MCL1-mediated mechanisms (Montalban-Bravo et al Cell Rep Med 2024). The purine analogue cladribine (CLAD) impairs nucleotide synthesis via ribonucleotide reductase inhibition and induces apoptosis of VEN-resistant AML monocytic clones. However, the distinct cell states spanning the monocytic spectrum and their role in CMML progression remains poorly understood.

To dissect CMML blast phenotypic diversity and its clinical implications, we used flow cytometry to evaluate a cohort of 98 patients (pts) with CMML. We quantified CD34+ myeloid blasts (CD45dimSSClowCD34+CD19-) and immature monocytes (ImMono) (CD45dimSSCintCD34-CD13dim/-CD33brightCD64brightCD14dim/-CD4+CD36+CD123+CD117dim/-). Both CD34+ myeloid blasts (r=0.5055, p<0.0001) and ImMono (r=0.3275, p=0.0012) frequencies correlated with morphologically defined blasts and monocytic blast equivalents though intra-patient analysis revealed heterogeneity in how each population contributed to blast frequencies. Among pts with BM excess blasts (n=32), we identified distinct subsets defined by either expansion of CD34+ myeloid progenitors (CD34+-bias) or ImMonos (ImMono-bias), a distinction confirmed by mass cytometry by time-of-flight (CyTOF) in two representative cases. Presence of ImMono correlated with multi-hit TET2 (65% vs 44%, p=0.041), SRSF2 (63% vs 34%, p=0.005), IDH2 (10% vs 0%, p=0.025) and SRSF2/TET2 co-mutation (63% vs 37%, p=0.025). Among a cohort of pts with CMML transformed to AML (n=18) progression to acute monocytic leukemia (MonoAML) or primitive AML (MyAML) arose from ImMono or CD34+ myeloid blast expansion, respectively. Longitudinal analysis at diagnosis and at transformation confirmed ImMono expansion in MonoAML (n=7) and of CD34+ myeloid blast expansion in MyAML (n=11).

To characterize the biology of these populations we performed single-cell RNA-sequencing of BM mononuclear cells (MNCs) from pts with either CD34+-bias (n=3) or ImMono-bias (n=3). Consistent with the flow cytometry data, ImMono-bias was associated with expansion of monocyte-committed cell populations including granulomonocytic progenitors (GMP), promonocytes (promono) and monocyte-derived dendritic cells (monoDC). GMPs were characterized by expression of E2F target and cell cycle genes including genes involved in de novo purine/pyrimidine synthesis (e.g RRM1, RRM2, TYMS, DHFR, GART) while promonos expressed NFkB signaling genes such as the antiapoptotic molecule MCL1.

To test whether purine metabolism inhibition impairs survival and induces apoptosis of HMA- or HMA/VEN-resistant progenitor and ImMono populations, we performed longitudinal flow cytometry (n=23) and scRNA-seq (n=4) on BM samples from pts enrolled in an ongoing prospective phase II trial of CLAD combined with low-dose cytarabine and VEN. This combination depleted CD34+ HSPCs and ImMonos and ImMono reduction correlated with RASp and RUNX1 mutant clone reduction. Promono and monoDC, which were increased at baseline, were depleted at the time of response and had reduced expression of genes involved in cell cycle, mTORC1 signaling and TNF-a signaling via NFkB at response. Therapy also downregulated gene networks critical to monocyte differentiation and inflammatory function in BM monocytes, and reduced MCL1 expression levels in HSPCs. Longitudinal CyTOF of BM MNCs is underway to dynamically evaluate MCL1, NF-kB and RAS signaling in HSPCs and ImMonos. In a representative responder, sc-RNA-seq showed depletion of promonos and monoDCs that mirrored ImMono depletion by flow cytometry, accompanied by VAF reduction in KRASA146T (5% vs 7%), KRASG12R (5% vs 28%), TET2G1169fs (17% vs 46%), TET2Q1537fs (13% vs 37%) and TET2Q1548dup (13% vs 36%) clones.

Together, these data indicate that CMML is characterized by distinct patterns of maturation arrest along the monocytic spectrum that dictate the phenotypic trajectories of disease transformation and can be depleted through combined purine/pyrimidine and BCL2 inhibition.

Guillermo Montalban-Bravo, MD: Solu Therapeutics - Research Funding; Rigel Pharmaceuticals - Research Funding; Takeda Oncology - Research Funding